Nearly 75 young athletes participated in the second UnitedHealthcare IRONKIDS® Seattle Fun Run today at Genesee Park. UnitedHealthcare mascot Dr. Health E. Hound kicked-off the fun run, joined by Sylvia Villalovos-Aguilar, UnitedHealthcare Community Plan of Washington.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150822005007/en/

Local youth take off at the second UnitedHealthcare IRONKIDS Seattle Fun Run today at Genesee Park.  …

Local youth take off at the second UnitedHealthcare IRONKIDS Seattle Fun Run today at Genesee Park. UnitedHealthcare mascot Dr. Health E. Hound kicked-off the fun run, joined by Sylvia Villalovos-Aguilar, UnitedHealthcare Community Plan of Washington. For the first time in Washington, IRONKIDS offered 1-mile and ¼-mile tracks for physically challenged youth athletes. Source: Kim Doyel ocal athletes, ages 3-15, had the opportunity to run along portions of the Iron Girl Seattle course, which takes place tomorrow. For the first time in Washington, IRONKIDS offered 1-mile and ¼-mile tracks for physically challenged youth athletes. At the start of the fun run, Villalovos-Aguilar presented a check for $3,000 to local community partner Victory Outreach Children’s Ministry to help promote the organization’s free programs for Seattle youth.

“The IRONKIDS fun run is a great way for our community to come together in an active and healthy way and to teach our youth the importance of a healthy lifestyle,” said Doug Bowes, CEO, UnitedHealthcare Community Plan of Washington. “UnitedHealthcare is grateful for the opportunity to partner with IRONMAN and the Victory Outreach Children’s Ministry.”

This is the fourth year UnitedHealthcare is supporting IRONKIDS as part of the company’s commitment to help stem the rising tide of childhood obesity through healthy lifestyles. The UnitedHealthcare IRONKIDS 2015 Series features nine one-mile fun-runs and a dip-and-dash.

Obesity among children and adolescents has almost tripled since 1980, with nearly one in every three children being overweight or obese, according to the U.S. Centers for Disease Control and Prevention (CDC). Children from low-income and low-education households are three-times more likely to suffer from obesity, which is a leading risk factor for diabetes, heart disease and many cancers, according to America’s Health Rankings®, an annual comprehensive assessment of the nation’s health on a state-by-state basis. Washington ranks 18th in the country with nearly 27 percent of adults estimated to be obese.

“We are thrilled to have a partner in UnitedHealthcare to sponsor these youth events as part of our IRONMAN series,” said Carola Ross, Chief Sales Officer for IRONMAN. “The opportunity the IRONKIDS fun-runs offer young athletes is tremendous, as these races can be the catalyst for a lifetime of exercise and healthy living.”

About IRONKIDS®

After being acquired from the Sara Lee Corporation, which owned the event series since 1985, IRONKIDS® launched in 2009 with nine events in the IRONKIDS® National Triathlon Series. Since the inaugural year, IRONKIDS® has seen more than 60,000 participants and has grown to more than 60 events worldwide including races in Africa, Asia, Australia, Europe and North America. The brand represents a multi-dimensional approach to creating positive experiences for athletes, families and communities, as well as embodies achievement and determination while fostering self-esteem. The IRONKIDS® mission is to inspire and motivate through the sport to live an active, positive and healthy lifestyle. For more information visit www.ironkids.com.

Melanoma–a very dangerous form of cancer–is in the news, largely due to recent announcements regarding the health of former U.S. President Jimmy Carter.

In light of President Carter's ongoing battle, Dermatologist Elizabeth Houshmand, M.D., FAAD, director of the Dermatology Division of SKINTASTIC Cosmetic Surgery and Laser Skin Care Centers, is strongly recommending annual skin cancer checks to all patients.

"The most effective treatment for melanoma is early and regular detection," Dr. Houshmand tells her patients. "In the case of melanoma, ignoring it and hoping it will go away just isn't an option." Melanoma is not the most common of the skin cancers, but it is the most insidious. Melanoma can be treated and cured if caught early.

Melanomas occur most often on the legs of women, and in men, melanomas are found most often on the back. Detected skin melanomas can usually be removed surgically. They range from a thin layer on the surface of the epidermis, to four millimeters deep into the fat layer of the skin. If not detected early, melanomas can spread on the skin, and through the blood to the brain, lymph nodes, bones, lungs, liver, and abdomen.

Mylan N.V. (NASDAQ: MYL) today clarified certain inaccuracies by third parties related to Mylan having lowered the acceptance condition in its offer to acquire Perrigo Company plc (NYSE: PRGO; TASE) from not less than 80% of Perrigo ordinary shares to greater than 50% of Perrigo ordinary shares.

Mylan Executive Chairman Robert J. Coury commented, "As we have stated repeatedly, Mylan remains fully confident that Perrigo's shareholders will see the value in this compelling combination and that more than 80% of Perrigo ordinary shares will be tendered into Mylan's offer, once launched following the approval of Mylan shareholders. With that said, Mylan is fully committed and prepared to operate Perrigo as a controlled subsidiary of Mylan in the unlikely event that greater than 50%, but less than 80%, of Perrigo ordinary shares are tendered and we would like to clarify certain implications of such a situation.  

"Specifically, it is important to note that Mylan would have the ability to pass Perrigo ordinary resolutions, which will allow us to control the composition of Perrigo's Board of Directors and management team, and to effectively control Perrigo's day-to-day operations. In addition, Mylan is satisfied that the cash flows of the Mylan-Perrigo combination can be appropriately and efficiently utilized in both controlled and wholly-owned subsidiary scenarios.

"Further, as discussed in Mylan's proxy materials, Mylan continues to believe that the combination  can realize annual pre-tax anticipated operational synergies of at least $800 million from the combined operations by the end of year four and that Mylan can successfully manage any additional risks associated with operating Perrigo as a controlled subsidiary, if necessary. Mylan has previous experience operating controlled subsidiaries, specifically when we acquired approximately 71% of Matrix Laboratories Limited in 2007 and operated it as a controlled subsidiary until 2015.

"We remain confident that we will receive the support of Mylan shareholders and that acquiring Perrigo is the right next strategic step for Mylan and its shareholders in continuing to deliver on our stellar track record of creating significant and sustained value for our shareholders and other stakeholders. We continue to look forward to making the combination with Perrigo a reality in the coming months."

On April 24, 2015, Mylan issued a Rule 2.5 announcement (amended on April 29, 2015) under the Irish Takeover Rules setting forth its legally-binding commitment to commence an offer directly to the Perrigo shareholders for the entire issued and to be issued share capital of Perrigo.  On Aug. 13, 2015, Mylan announced that it had exercised its option to formally reduce the acceptance condition to its offer by lowering the acceptance threshold from not less than 80% of Perrigo ordinary shares to greater than 50% of Perrigo ordinary shares.   The proposed transaction remains subject to certain conditions and other terms set forth in the formal Rule 2.5 announcement.

ABOUT MYLAN

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.

RESPONSIBILITY STATEMENT

The directors of Mylan accept responsibility for the information contained in this communication. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case) the information contained in this communication is in accordance with the facts and does not omit anything likely to affect the import of such information.

DEALING DISCLOSURE REQUIREMENTS

Under the provisions of Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the "Irish Takeover Rules"), if any person is, or becomes, 'interested' (directly or indirectly) in, 1% or more of any class of 'relevant securities' of Perrigo or Mylan, all 'dealings' in any 'relevant securities' of Perrigo or Mylan (including by means of an option in respect of, or a derivative referenced to, any such 'relevant securities') must be publicly disclosed by not later than 3:30 pm (New York time) on the 'business' day following the date of the relevant transaction. This requirement will continue until the date on which the 'offer period' ends. If two or more persons co-operate on the basis of any agreement, either express or tacit, either oral or written, to acquire an 'interest' in 'relevant securities' of Perrigo or Mylan, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.

Under the provisions of Rule 8.1 of the Irish Takeover Rules, all 'dealings' in 'relevant securities' of Perrigo by Mylan or 'relevant securities' of Mylan by Perrigo, or by any party acting in concert with either of them, must also be disclosed by no later than 12 noon (New York time) on the 'business' day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, can be found on the Irish Takeover Panel's website at www.irishtakeoverpanel.ie.nterests in securities arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.erms in quotation marks are defined in the Irish Takeover Rules, which can also be found on the Irish Takeover Panel's website. If you are in any doubt as to whether or not you are required to disclose a dealing under Rule 8, please consult the Irish Takeover Panel's website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020 or fax number +353 1 678 9289.

Goldman Sachs, which is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting for Mylan and no one else in connection with the Perrigo Proposal and will not be responsible to anyone other than Mylan for providing the protections afforded to clients of Goldman Sachs, or for giving advice in connection with the Perrigo Proposal or any matter referred to herein.

Goldman Sachs does not accept any responsibility whatsoever for the contents of this communication or for any statement made or purported to be made by them or on their behalf in connection with the offer. Goldman Sachs accordingly disclaims all and any liability whether arising in tort, contract or otherwise which it might otherwise have in respect of this communication or any such statement.

ADDITIONAL INFORMATION

In connection with the Perrigo Proposal, Mylan has filed certain materials with the SEC (and anticipates filing further materials), including, among other materials, the Registration Statement and the Proxy Statement. In connection with the Perrigo Proposal, Mylan currently intends to file with the SEC a Tender Offer Statement on Schedule TO and certain other materials. This communication is not intended to be, and is not, a substitute for such filings or for any other document that Mylan may file with the SEC in connection with the Perrigo Proposal. INVESTORS AND SECURITYHOLDERS OF MYLAN AND PERRIGO ARE URGED TO READ THE DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY (IF AND WHEN THEY BECOME AVAILABLE) BEFORE MAKING AN INVESTMENT DECISION BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MYLAN, PERRIGO AND THE PERRIGO PROPOSAL. Such documents will be available free of charge through the website maintained by the SEC at www.sec.gov or by directing a request to Mylan at 724-514-1813 or investor.relations@mylan.com. Any materials filed by Mylan with the SEC that are required to be mailed to shareholders of Perrigo and/or Mylan will also be mailed to such shareholders. Mylan first began mailing the Proxy Statement to its shareholders on or about July 31, 2015. This communication has been prepared in accordance with U.S. securities law, Irish law, and the Irish Takeover Rules.

A copy of this communication will be available free of charge at the following website: perrigotransaction.mylan.com. Such website is neither endorsed, nor sponsored, nor affiliated with Perrigo or any of its affiliates. PERRIGO® is a registered trademark of L. Perrigo Company.

PARTICIPANTS IN SOLICITATION

This communication is not a solicitation of a proxy from any investor or shareholder. However, Mylan and certain of its directors, executive officers, and other members of its management and employees may be deemed to be participants in the solicitation of proxies in connection with the Perrigo Proposal under the rules of the SEC. Information regarding Mylan's directors and executive officers may be found in Mylan Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, which was filed with the SEC on March 2, 2015, amended on April 30, 2015, and updated by Mylan's Current Report on Form 8-K filed on June 11, 2015, as well as in the Registration Statement and the Proxy Statement. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the interests of these participants, which may, in some cases, be different than those of Mylan's shareholders generally, will also be included in the materials that Mylan intends to file with the SEC when they become available.

NON-SOLICITATION

This communication is not intended to, and does not, constitute or form part of (1) any offer or invitation to purchase or otherwise acquire, subscribe for, tender, exchange, sell or otherwise dispose of any securities, (2) the solicitation of an offer or invitation to purchase or otherwise acquire, subscribe for, sell, or otherwise dispose of any securities, or (3) the solicitation of any vote or approval in any jurisdiction pursuant to this communication or otherwise, nor will there be any acquisition or disposition of the securities referred to in this communication in any jurisdiction in contravention of applicable law or regulation. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

SYNERGY STATEMENT

There are various material assumptions underlying the statement relating to "at least US $800 million of annual pre-tax operational synergies" (the "Synergy Statement"), which may result in the value in the Synergy Statement being materially greater or less than estimated. The Synergy Statement should therefore be read in conjunction with the key assumptions underlying such estimates which are set out in Mylan's announcement pursuant to Rule 2.5 of the Irish Takeover Rules on April 24, 2015 (the "2.5 Announcement").
The Synergy Statement should not be construed as a profit forecast or interpreted to mean that the combined earnings of Mylan and Perrigo in any period following this communication would necessarily match or be greater than or be less than those of Mylan and/or Perrigo for the relevant preceding financial period or any other period.

The information set forth under "About Mylan" above has been extracted from Mylan Inc.'s Annual Report (Form 10-K) for the period ended December 31, 2014 filed with the SEC on March 2, 2015, amended on April 30, 2015 and updated by Mylan's Current Report on Form 8-K filed on June 11, 2015.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mylan-clarifies-certain-inaccuracies-by-third-parties-related-to-lowered-acceptance-condition-to-acquire-perrigo-300131910.html
SOURCE Mylan N.V.

A new study published today in the journal, Neuropsychiatric Disease and Treatment, is being hailed as a "medical breakthrough" in the treatment of traumatic brain injury (TBI), which plagues millions of athletes, military veterans and first-responder professionals.

Photo – http://photos.prnewswire.com/prnh/20150821/260217

The study, "Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy," found that a specific high-powered, near infrared light (NIR) can effectively re-energize damaged brain cells after penetrating the skin and skull. All the patients in the study reported significant clinical improvement in their condition with no negative side effects, according to Theodore Henderson, MD, PhD, who co-authored the study along with Dr. Larry Morries, and Paolo Cassano of Massachusetts General. This is the second largest study of NIR for brain injury and the only one using the more powerful Class-IV laser to deliver NIR, Dr. Henderson said.

"This is a real game changer," said Dr. Henderson, co-founder of the Neuro-Laser Foundation, "because these patients have retained the benefits for up to four years now. For those who have been told there is no treatment for TBI, we invite you to look closely at what we've found and you will regain hope."

The Centers for Disease Control report over 2.5 million emergency visits for concussions and TBI annually, said Dr. Henderson. Athletes with multiple sub-concussive blows and military veterans with TBI (over 307,000) also have lasting symptoms. These symptoms can include headaches, speech irregularities, confusion, memory slips, lack of impulse control, sleep disturbance, anxiety, depression, and for some, suicide.

"Patients from the study experienced a significant reduction of their depressive symptoms as demonstrated using standardized depression scales," Dr. Henderson said. "They all improved dramatically. Headaches, depression, anxiety, insomnia, irritability, mood swings, sleep problems, and relationship problems all resolved. Several unemployed patients returned to work or started new careers."

The study occurred from 2011-2013 with 10 people diagnosed with chronic mild-to-moderate TBI as a result of involvement in athletics, military activities or as first-responders. The treatments included 10 transcranial applications of high-power NIR over the course of two months. Using a Class IV laser and pulsed light, each treatment took less than 60 minutes. Previous studies with low-powered NIR had shown on transient benefits. In this study, Morries and colleagues report benefits lasting for years after treatment.

The exciting news is that NIR light, in the 10-15W range at 810 nm and 980 nm, can safely and effectively treat chronic symptoms of TBI, Dr. Henderson said. However, he cautions that low-powered NIR or diode-based infrared light does not even penetrate the skin, so not every type of NIR treatment would be as effective as what Dr. Morries and colleagues have published here.

"We have seen the effectiveness of NILT transform people's lives. Now, we plan on making this treatment more widely available," said Dr. Henderson.

The Neuro-Laser Foundation (NLF) is a non-profit organization based in Denver, Colorado, dedicated to advancing technology and treatment that will increase quality of life for people impacted by traumatic brain injury and other complex psychiatric conditions.

A new study published today in the journal, Neuropsychiatric Disease and Treatment, is being hailed as a "medical breakthrough" in the treatment of traumatic brain injury (TBI), which plagues millions of athletes, military veterans and first-responder professionals.

Photo – http://photos.prnewswire.com/prnh/20150821/260217

The study, "Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy," found that a specific high-powered, near infrared light (NIR) can effectively re-energize damaged brain cells after penetrating the skin and skull. All the patients in the study reported significant clinical improvement in their condition with no negative side effects, according to Theodore Henderson, MD, PhD, who co-authored the study along with Dr. Larry Morries, and Paolo Cassano of Massachusetts General. This is the second largest study of NIR for brain injury and the only one using the more powerful Class-IV laser to deliver NIR, Dr. Henderson said.

"This is a real game changer," said Dr. Henderson, co-founder of the Neuro-Laser Foundation, "because these patients have retained the benefits for up to four years now. For those who have been told there is no treatment for TBI, we invite you to look closely at what we've found and you will regain hope."

The Centers for Disease Control report over 2.5 million emergency visits for concussions and TBI annually, said Dr. Henderson. Athletes with multiple sub-concussive blows and military veterans with TBI (over 307,000) also have lasting symptoms. These symptoms can include headaches, speech irregularities, confusion, memory slips, lack of impulse control, sleep disturbance, anxiety, depression, and for some, suicide.

"Patients from the study experienced a significant reduction of their depressive symptoms as demonstrated using standardized depression scales," Dr. Henderson said. "They all improved dramatically. Headaches, depression, anxiety, insomnia, irritability, mood swings, sleep problems, and relationship problems all resolved. Several unemployed patients returned to work or started new careers."

The study occurred from 2011-2013 with 10 people diagnosed with chronic mild-to-moderate TBI as a result of involvement in athletics, military activities or as first-responders. The treatments included 10 transcranial applications of high-power NIR over the course of two months. Using a Class IV laser and pulsed light, each treatment took less than 60 minutes. Previous studies with low-powered NIR had shown on transient benefits. In this study, Morries and colleagues report benefits lasting for years after treatment.

The exciting news is that NIR light, in the 10-15W range at 810 nm and 980 nm, can safely and effectively treat chronic symptoms of TBI, Dr. Henderson said. However, he cautions that low-powered NIR or diode-based infrared light does not even penetrate the skin, so not every type of NIR treatment would be as effective as what Dr. Morries and colleagues have published here.

"We have seen the effectiveness of NILT transform people's lives. Now, we plan on making this treatment more widely available," said Dr. Henderson.

The Neuro-Laser Foundation (NLF) is a non-profit organization based in Denver, Colorado, dedicated to advancing technology and treatment that will increase quality of life for people impacted by traumatic brain injury and other complex psychiatric conditions.

The University of Texas System Board of Regents has approved establishment of the UT Southwestern Monty and Tex Moncrief Medical Center at Fort Worth, made possible by an extraordinary $25 million commitment from W.A. "Tex" Moncrief Jr. The Center is UT Southwestern's first named campus outside of Dallas.

The new campus in the heart of Fort Worth's burgeoning medical district will build on UT Southwestern Medical Center's recent expansions at the Moncrief Cancer Institute. It also strengthens the Medical Center's capacity to serve residents of Fort Worth and surrounding areas, improving access to UT Southwestern's medical care, research, and educational opportunities.

"The UT Southwestern Monty and Tex Moncrief Medical Center recognizes the long-standing support and vision of the Moncrief family, which has enabled our growing clinical presence in Fort Worth," said Dr. Daniel K. Podolsky, President of UT Southwestern. "In the years ahead, their remarkable generosity will support the development of a multidisciplinary outpatient facility programmed specifically to meet the medical needs of the area. We are delighted and privileged to be a part of the growing Fort Worth community."

The first building on the 6.3-acre site, located at the intersection of Pennsylvania Avenue and Main Street, is expected to be completed in September 2016 and will offer the expertise of UT Southwestern faculty specialty physicians at a multidisciplinary outpatient facility.

"My Dad would be pleased that the Moncrief Radiation Center that he created in Fort Worth years ago has now evolved into UT Southwestern's plan for a major clinic in Fort Worth to help take care of the medical needs of the citizens of Fort Worth and North Texas," said W.A. "Tex" Moncrief Jr., President of the William A. and Elizabeth B. Moncrief Foundation, which contributes to educational, health, civic, and cultural organizations. "UT Southwestern is known worldwide as a premier academic medical center that is fundamentally changing medicine through excellent clinical care, groundbreaking research, and the outstanding education it provides the next generation of physicians and caregivers."

Over the years, the Moncrief family has provided nearly $14 million from the William A. and Elizabeth B. Moncrief Foundation and from Tex Moncrief in direct support of UT Southwestern programs at its Dallas campus, as well as $75 million in funds given to the Moncrief Cancer Foundation in support of the UT Southwestern Moncrief Cancer Institute in Fort Worth.

In Dallas, the W.A. Monty & Tex Moncrief Radiation Oncology Building, adjacent to the Seay Biomedical Building at UT Southwestern, offers state-of-the-art radiation therapy and research equipment, and houses the Department of Radiation Oncology. The W. A. (Monty) Moncrief Distinguished Chair in Cholesterol and Arteriosclerosis Research is held by Nobel Laureate Dr. Michael Brown, who is also currently the Paul J. Thomas Professor of Molecular Genetics and Director of the Jonsson Center for Molecular Genetics at UT Southwestern.

"With this magnificent $25 million gift from Mr. Moncrief, UT Southwestern will be able to expand its presence in the Fort Worth area, providing advanced specialty care, access to clinical trials, and expertise that only an academic medical center can provide. This continues an era of growth for UT Southwestern," said Dr. Podolsky, who holds the Philip O'Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science.

Fort Worth Mayor Betsy Price acknowledged the importance of the new Center. "One of my top priorities as Mayor has always been the health and well-being of our citizens. I'm delighted that UT Southwestern is expanding in Fort Worth, bringing even greater depth and dimension to the medical services available here," she said. "The Moncrief family is much more than a benefactor to this city. They have truly changed the landscape."

Tarrant County Judge Glen Whitley noted the expansion will benefit residents throughout Tarrant County and beyond. "UT Southwestern is a valuable partner in helping to ensure that residents from across the county and surrounding regions have access to the capabilities of this extraordinary academic medical center. Because of UT Southwestern's commitment, our residents benefit from top-tier care and the most advanced medical innovations."

New Campus to Provide Diverse Collection of Services

The campus will encompass the newly acquired property and the facility to be built there and the Moncrief Cancer Institute, located on a nearby 3.4-acre site at 400 W. Magnolia Ave. The latter Moncrief Cancer Institute supports North Texas cancer survivors, especially medically underserved adults, by focusing on prevention, research, and survivorship programs. The facility offers services that include genetic counseling, mammography screening, nutritional counseling, and healthy cooking classes. A telemedicine unit also allows the staff to provide testing and risk assessment to patients in surrounding and outlying counties. 

Dee J. Kelly, Sr., founding partner of Kelly Hart & Hallman LLP, who serves on the board of directors of the Moncrief Cancer Foundation, noted, "This fulfills a lifelong effort by Tex to honor his father by enabling UT Southwestern Medical Center to construct and operate a clinic in Fort Worth that will provide medical services that are innovative and unique, and will directly benefit the citizens of our community. This new outpatient facility builds upon and works closely with UT Southwestern's Moncrief Cancer Institute to offer additional and complementary clinical services."

In May, UT Southwestern opened facilities within the Moncrief Cancer Institute to provide easy access to the clinical expertise and services of the Harold C. Simmons Comprehensive Cancer Center for residents of Tarrant and 10 surrounding counties. This facility includes exam space, state-of-the-art imaging capabilities, on-site lab and pharmacy services, and 14 all-private infusion rooms for chemotherapy – which was a first for Fort Worth.

Secure telemedicine directly links to the Simmons Cancer Center in Dallas, allowing convenient access to consultations and secured access to electronic medical records, as well as extending the reach of oncologists, surgeons, and bone marrow transplant specialists at UT Southwestern's William P. Clements Jr. University Hospital and radiation oncologists at the W.A. Monty & Tex Moncrief Radiation Oncology Building.

In February 2015, the Moncrief Cancer Institute and Simmons Cancer Center debuted the Mobile Cancer Survivor Clinic – a custom-designed, $1.1 million, fully equipped 18-wheeler that can deliver follow-up and screening services to cancer survivors in their communities. The traveling clinic serves Tarrant, Parker, Wise, Hood, Erath, Somervell, Johnson, Ellis, and Navarro counties – a region where 55 percent of the population is considered medically underserved and where one-third of cancer survivors are considered at risk of failing to adhere to essential follow-up care due to the lack of facilities, lack of transportation, and other factors. The bilingual Mobile Cancer Survivor Clinic offers 3-D mammography, colon cancer screenings, private exam rooms, exercise facilities for one-on-one training, and high-speed telemedicine links to cancer experts and counseling services at UT Southwestern.

About W.A. "Monty" Moncrief

Mr. W.A. "Monty" Moncrief was one of Texas' legendary wildcatters. In 1931, he drilled one of the first wells in the East Texas oil field and made a major discovery extending the field. The Lathrop well came in at 18,000 barrels a day. The market was flooded with East Texas oil. Moncrief and his partners decided to sell their East Texas interest for $2.5 million. It later sold for over $37 million to Standard Oil Company. Mr. Moncrief then used the funds from the sale of his East Texas property to discover other major fields in West Texas, Florida and Louisiana.

About W.A. "Tex" Moncrief, Jr.

W.A. "Tex" Moncrief Jr. was born in 1920 in Fort Worth, and later graduated from the University of Texas in 1942 with a degree in petroleum engineering. After working as an engineer in the East Texas oil fields, he received a commission in the U.S. Naval Reserve and was trained at Harvard as a communications officer before serving in the Pacific.

After the war, he returned to Fort Worth and went into the oil business with his father. It was Tex Moncrief who made huge discoveries of natural gas in Wyoming, as well as major discoveries on the Gulf coast, in Texas and Louisiana.

Mr. Tex Moncrief has also been a huge supporter of athletics at the University of Texas and Texas Christian University, where the field is named after him and his father. Tex served on the Board of Regents from 1987 to 1993 and was named to the Texas Philanthropy Hall of Fame in 2001 and was honored as a Distinguished Alumnus by the University of Texas Exes in 2008.

About UT Southwestern Medical Center

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution's faculty includes many distinguished members, including six who have been awarded Nobel Prizes since 1985. The faculty of more than 2,700 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to about 92,000 hospitalized patients and oversee approximately 2.1 million outpatient visits a year.

The Department of Drug and Alcohol Programs (DDAP) today officially launched its Facebook and Twitter pages to provide better outreach to Pennsylvanians about substance use disorder and reach more individuals who need help finding services for substance use disorder.

"By launching these social media sites, we are working to provide a resource that will help address the epidemic of addiction in Pennsylvania," said DDAP Secretary Gary Tennis. "It is important for our department to help break down the stigma which surrounds addiction, by creating a platform where people can share stories about the importance of treatment services, and to provide an outlet to reach individuals or their loved ones who are struggling with substance use disorders."

Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has priced its previously announced underwritten public offering of common stock consisting of 4,878,049 shares at a public offering price of $41.00 per share. Gross proceeds to Intrexon from this offering are expected to be approximately $200 million and Intrexon intends to use the net proceeds from this offering for general corporate purposes as well as for strategic acquisitions or investments.

Intrexon Corporation logo

Intrexon has granted the underwriters a 30-day option to purchase up to an additional 731,707 shares of common stock offered in the public offering. All of the shares in the offering will be sold by Intrexon. The offering is expected to close on August 26, 2015, subject to customary closing conditions. JMP Securities LLC is acting as sole book-running manager and Stifel is acting as lead manager for the offering. Griffin Securities and Wunderlich Securities are acting as co-managers for the offering.

The public offering is being made pursuant an automatic shelf registration statement on Form S-3ASR that was previously filed with the Securities and Exchange Commission (SEC). A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. When available, copies of the final prospectus supplement and accompanying base prospectus relating to the offering may also be obtained from JMP Securities LLC, 600 Montgomery Street, Suite 1100, San Francisco, California  94111 or by telephone: +1 (415) 835-8985.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Intrexon Corporation

Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet.  The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells.  We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com. 

Trademarks

Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

DST Systems, Inc. (NYSE: DST), a global provider of strategically unified data management, business processing, and customer communication solutions, today announced it has completed the previously announced acquisition of retirement plan rollover specialist Wealth Management Systems Inc. (WMSI).

DST Systems, Inc.

New York-based WMSI, a leading provider of retirement plan rollover technology, content and communications, and practice management solutions to the financial services industry, is connected to recordkeepers servicing over 33 million participants and provides automatic rollover services to over 25,000 plan sponsors.

"I'm confident that recordkeepers, sponsors, asset managers, TPAs, and financial advisors working in the retirement space will benefit from the remarkable synergy between DST and WMSI," said Jude Metcalfe, president of DST Retirement Solutions. "Our combined resources, capabilities, and commitment promise to bring an unmatched opportunity for our clients to grow and retain retirement assets."

As part of the DST enterprise, WMSI's comprehensive suite of services and rollover solutions will come to market as part of DST Retirement Solutions, a leading provider of defined contribution technology, strategic advisory, and business processing solutions to the retirement industry.

About DST

DST Systems, Inc. is a leading provider of sophisticated information processing and servicing solutions to companies around the world. Through its global enterprise, DST delivers strategically unified transactions and business processing, data management, and customer communications solutions to the asset management, brokerage, retirement, and healthcare markets. Headquartered in Kansas City, MO, DST is a publicly-traded company on the New York Stock Exchange. For more information, visit www.dstsystems.com.

Media Contact:
Laura M. Parsons                              
DST Global Public Relations
816.843.9087      
mediarelations@dstsystems.com

C4 Imaging LLC today announced it has been awarded a $1.32 Million Phase II Small Business Innovation Research ("SBIR") grant from the National Cancer Institute of the National Institutes of Health ("NIH").  Entitled "Multi-Modality MRI/CT Markers for Improved Assessment of Prostate Cancer," the Phase II SBIR award will help fund the development of an enhanced multi-modality imaging marker based on C4 Imaging's commercially available Sirius™ MRI Marker.

This is the second NIH SBIR award for C4 Imaging.  C4 Imaging has successfully demonstrated a MRI Marker approach for radioactive seed localization that addresses the need to improve treatment assessment for men who undergo prostate brachytherapy.  Sirius™ is FDA approved for implantation in prostate cancer patients being treated with radioactive seeds (brachytherapy).  Its function is based on the unique paramagnetic properties of C4 Imaging's proprietary C4 solution.  This core technology was awarded a US patent in September 2013, with additional patent protection for further applications awarded in September 2014.  An enhanced, multi-modality version of the device will allow clinicians to utilize multiple imaging modalities for optimal anatomical visualization to improve treatment planning and assessment across a range of diseases.

"This phase II SBIR award is a significant achievement for us," said Andrew Bright, President and CEO of C4 Imaging. "It provides over $1 Million to support the further development of our patented C4 technology.  With this award, we can now accelerate our plans to develop additional MRI focused products for cancer patients within a large and growing MRI market."

The Phase II SBIR award will support a detailed development program; including product design, validation and manufacture, along with pre-clinical and clinical testing that will be performed in collaboration with the University of Texas MD Anderson Cancer Center.

About C4 IMAGING
C4 Imaging LLC develops innovative medical devices that enable clinicians to personalize patient treatment through accurate, image-guided procedures.  The company's core proprietary technology, C4, has been developed as Sirius™ the first commercially available Positive-Signal MRI Marker.  Further information is available at www.c4imaging.com.  The research described in this news release will be supported by the National Cancer Institute of the National Institutes of Health under Award Number R44CA199905.  The content is solely the responsibility of C4 Imaging and does not necessarily represent the official views of the National Institutes of Health.